


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:21Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406993" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406993</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JCO Precis Oncol</journal-id><journal-id journal-id-type="iso-abbrev">JCO Precis Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">PO</journal-id><journal-title-group><journal-title>JCO Precision Oncology</journal-title></journal-title-group><issn pub-type="epub">2473-4284</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406993</article-id><article-id pub-id-type="pmcid-ver">PMC12406993.1</article-id><article-id pub-id-type="pmcaid">12406993</article-id><article-id pub-id-type="pmcaiid">12406993</article-id><article-id pub-id-type="pmid">40865030</article-id><article-id pub-id-type="doi">10.1200/PO-25-00214</article-id><article-id pub-id-type="publisher-id">PO-25-00214</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Cancer Genetics</subject></subj-group></subj-group></article-categories><title-group><article-title>Association of <italic toggle="yes">RPS20</italic> Loss-of-Function Variants With Colorectal Cancer Risk in a Cohort of Over 950,000 Individuals</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-7861-178X</contrib-id><name name-style="western"><surname>Herrera-Mullar</surname><given-names initials="J">Jennifer</given-names></name><degrees>MGC, DMA</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con1" ref-type="fn"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carraway</surname><given-names initials="C">Cassidy</given-names></name><degrees>BS</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con2" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6049-6931</contrib-id><name name-style="western"><surname>Marsh</surname><given-names initials="APL">Ashley P.L.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con3" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hernandez</surname><given-names initials="F">Felicia</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con4" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kudalkar</surname><given-names initials="E">Emily</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con5" ref-type="fn"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4626-4920</contrib-id><name name-style="western"><surname>Richardson</surname><given-names initials="ME">Marcy E.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="con6" ref-type="fn"/></contrib><aff id="aff1"><label><sup>1</sup></label>Ambry Genetics Corporation, Aliso Viejo, CA</aff></contrib-group><author-notes><corresp id="cor1">Jennifer Herrera-Mullar, MGC, DMA; e-mail: <email>jherreramullar@ambrygen.com</email>.</corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2025</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">496166</issue-id><elocation-id>e2500214</elocation-id><history><date date-type="received"><day>11</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>20</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by American Society of Clinical Oncology</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="po-9-e2500214.pdf"/><self-uri xlink:href="po-9-e2500214.pdf"/><abstract><sec><title>PURPOSE</title><p><italic toggle="yes">RPS20</italic> is a proposed colorectal cancer (CRC) predisposition gene, with only four families with putative loss-of-function (pLoF) variants published. The prevalence, phenotypic spectrum, and clinical management recommendations for <italic toggle="yes">RPS20</italic> heterozygotes remain unknown.</p></sec><sec><title>METHODS</title><p>Retrospective review of approximately 950,000 individuals undergoing multigene panel testing (MGPT) for cancer predisposition identified 36 individuals with pLoF variants in <italic toggle="yes">RPS20</italic>. Clinical features, tumor prevalence, and age at onset were compared with Lynch syndrome (LS) and wild-type (WT) cohorts.</p></sec><sec><title>RESULTS</title><p>Thirty-six individuals (0.004%) had 28 unique pLoF variants in <italic toggle="yes">RPS20</italic> and a total of 42 primary tumors, 78.6% of which were CRC with a median age of diagnosis of 50 years. A total of 16.7% of individuals had multiple CRC primaries, and a majority (71.4%) were mismatch repair&#8211;proficient (pMMR). Signet ring cell (SRC) pathology was significantly enriched compared with WT (<italic toggle="yes">P</italic> = &lt;.0001). The odds ratio for CRC was significantly higher than that for the <italic toggle="yes">MLH1</italic>-related LS cohort (odds ratio [OR], 45.3 [95% CI, 21.3 to 101] and OR, 16.9 [95% CI, 14.9 to 19.2], respectively).</p></sec><sec><title>CONCLUSION</title><p><italic toggle="yes">RPS20</italic> is associated with early-onset, pMMR CRC enriched for SRC pathology. Comparison of prevalence showed a statistically significant two-fold increase in the odds of developing CRC compared with an <italic toggle="yes">MLH1</italic> LS cohort. These data confirm the gene-disease relationship between <italic toggle="yes">RPS20</italic> and CRC and support clinical management guidelines similar to <italic toggle="yes">MLH1</italic>-related LS.</p></sec></abstract><counts><fig-count count="1"/><table-count count="5"/><equation-count count="0"/><ref-count count="20"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>INTRODUCTION</title><p>Current genes associated with adult-onset hereditary colorectal cancer (CRC) explain &lt;20% of familial CRC.<sup><xref rid="b1" ref-type="bibr">1</xref></sup> Despite more comprehensive sequencing technologies, few new genes associated with hereditary CRC have been uncovered. In 2014, Nieminen, et al proposed <italic toggle="yes">RPS20</italic> (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001023.3">NM_001023.3</ext-link>) as a novel gene associated with highly penetrant, early-onset CRC.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> However, including this initial report, only six families with variants in <italic toggle="yes">RPS20</italic> have been described.<sup><xref rid="b3" ref-type="bibr">3</xref>-<xref rid="b6" ref-type="bibr">6</xref></sup> Four of these families harbor truncating variants,<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b4" ref-type="bibr">4</xref>-<xref rid="b6" ref-type="bibr">6</xref></sup> and two families harbor missense variants with an unknown functional impact.<sup><xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b5" ref-type="bibr">5</xref></sup> Because of the rarity of published cases, this gene-disease relationship (GDR) has remained uncharacterized with limited gene-disease validity (GDV), such that no variants can be classified above a variant of uncertain significance (VUS) per American College of Medical Genetics<sup><xref rid="b7" ref-type="bibr">7</xref></sup> and ClinGen guidelines.<sup><xref rid="b8" ref-type="bibr">8</xref></sup> Furthermore, currently published cases are from highly ascertained, small cohorts selected for suspicion of hereditary CRC, and these results have not been replicated or validated in larger, diverse cohorts. The actual prevalence of <italic toggle="yes">RPS20</italic>-related cancer predisposition remains unknown, as well as comprehensive phenotypic characterization (including specific tumor characteristics) or lifetime tumor risk estimates to guide clinical management recommendations for individuals with variants in <italic toggle="yes">RPS20</italic>. Additional data validating the role of <italic toggle="yes">RPS20</italic> in CRC or other cancer predisposition are crucial to inform genetic testing and guide individual patient management. Here, we present a series of 36 individuals with putative loss-of-function variants (pLoF, defined as truncating variants expected to undergo nonsense-mediated decay) in <italic toggle="yes">RPS20</italic> from a cohort of nearly one million individuals undergoing multigene panel testing (MGPT) for diverse cancer phenotypes. We provide the prevalence of <italic toggle="yes">RPS20</italic> pLoF alterations in a cancer cohort, a comprehensive phenotypic analysis of these individuals, and a comparison of the prevalence of various features between a Lynch syndrome (LS) and wild-type (WT) cohort. This analysis formally characterizes the GDR between <italic toggle="yes">RPS20</italic> and high-penetrance, early-onset CRC while also providing vital data to inform the clinical management of individuals with <italic toggle="yes">RPS20</italic> pLoF alterations.</p><boxed-text id="B1" position="anchor" orientation="portrait"><sec sec-type="context-box"><title>CONTEXT</title><p>
<list list-type="simple"><list-item><p>
<bold>Key Objective</bold>
</p></list-item><list-item><p>Are <italic toggle="yes">RPS20</italic> loss-of-function variants a definitive cause of high-penetrance, early-onset colorectal cancer (CRC)?</p></list-item><list-item><p>
<bold>Knowledge Generated</bold>
</p></list-item><list-item><p>The odds of CRC in the <italic toggle="yes">RPS20</italic> cohort were over 45 times higher compared with a similarly ascertained pan-cancer multigene panel testing cohort with negative results and more than twice as high as those in individuals with <italic toggle="yes">MLH1</italic>-related Lynch syndrome (LS). The <italic toggle="yes">RPS20</italic> cohort showed a significant association with both multiple primary CRCs and signet ring CRC (<italic toggle="yes">P</italic> &lt; .001).</p></list-item><list-item><p>
<bold>Relevance</bold>
</p></list-item><list-item><p>Our data confirm the association of <italic toggle="yes">RPS20</italic> with early-onset CRC predisposition, allowing for classification of variants as likely pathogenic or pathogenic, and indicate that the CRC risks are similar to or higher than those related to <italic toggle="yes">MLH1</italic>-related LS, providing important information for clinical management.</p></list-item></list>
</p></sec></boxed-text></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Datasets</title><sec><title>
Curated Datasets
</title><p>For comprehensive phenotypic characterization of the <italic toggle="yes">RPS20</italic> cohort, approximately 950,000 hereditary cancer (HC) MGPT were retrospectively reviewed. MGPT ranged from 17 genes to 91 reportable genes, and all cases had <italic toggle="yes">RPS20</italic> coverage as part of the library. The cohort contained individuals with confirmed heterozygous pLoF in <italic toggle="yes">RPS20</italic> between March 2017 and July 2024 (n = 36). Three individuals had <italic toggle="yes">RPS20</italic> ordered as a reportable finding, and in the remaining 33 cases, <italic toggle="yes">RPS20</italic> was not included in the gene list ordered. <italic toggle="yes">RPS20</italic> splicing variants were confirmed to result in premature termination via capture RNA-seq.<sup><xref rid="b9" ref-type="bibr">9</xref></sup> Clinical data and demographic information were obtained by requisition form or additional clinical documentation provided to this laboratory. Information regarding tumor burden, tumor type, tumor characteristics, gastrointestinal polyp history, age(s) of diagnosis, and family cancer and polyp history was recorded. Clinical features of the <italic toggle="yes">RPS20</italic> cohort were compared with those of a similarly ascertained, comprehensively curated cohort of 19,810 individuals with negative HC MGPT (76 genes; referred to as WT-curated).</p></sec><sec><title>
ICD10 Datasets
</title><p>International Classification of Diseases codes (ICD)10 datasets were built from a consecutive cohort of MGPT-tested patients ordering a germline-only test from January 2019 through April 2024. These datasets allowed for CRC prevalence comparison between the <italic toggle="yes">RPS20</italic> cohort and a large cohort of individuals with LS, serving as a positive control dataset. The use of ICD10 codes corresponding to CRC was validated against a large, manually curated data set, revealing a sensitivity of 86.3% and a specificity of 99.8% for CRC and a mean difference between age at onset and age at testing of 1.98 years (data not shown). Age at onset was not available in this dataset; therefore, age at testing was used in analyses. Codes corresponding to a CRC diagnosis are provided in <xref rid="app1" ref-type="app">Appendix 1</xref> .</p><p>Within this ICD10 cohort, 384,445 individuals with comprehensive HC testing (37-85 genes) were identified who had no VUS or (likely) pathogenic (LP/P) variants and comprised the WT-ICD10 dataset. In addition, within this ICD10 cohort, a total of 11,437 patients with LS were identified: <italic toggle="yes">MLH1</italic> LP/P (n = 1,077), <italic toggle="yes">MSH2</italic> LP/P (n = 2,610), <italic toggle="yes">MSH6</italic> LP/P (n = 3,650), or <italic toggle="yes">PMS2</italic> LP/P (n = 4,100).</p><p>Finally, 513 additional individuals with confirmed heterozygous missense variants in <italic toggle="yes">RPS20</italic> were identified in this ICD10 cohort to determine CRC prevalence. Missense variants with a filtering allele frequency of &#8805;0.00735% were excluded because they were above the maximum credible frequency for a disease-causing variant in <italic toggle="yes">RPS20</italic>.<sup><xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref></sup> Missense variants were assessed in aggregate and stratified based on their predicted deleteriousness using BayesDel,<sup><xref rid="b12" ref-type="bibr">12</xref></sup> an in silico metapredictor of variant effect, for comparisons with ICD10-WT (Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>).</p></sec></sec><sec sec-type="methods"><title>Statistical Methods</title><p>Demographics and clinical characteristics of the comprehensively curated <italic toggle="yes">RPS20</italic> cohort were compared with those of the WT-curated cohort using Fisher's exact test, and age at testing, first cancer, and first CRC diagnosis were tested using the Wilcoxson rank-sum test (Table <xref rid="tbl1" ref-type="table">1</xref>). The prevalence of CRC among the ICD10 data sets for <italic toggle="yes">RPS20</italic> pLoF and LS probands was plotted and compared with that of the WT-ICD10 using Fisher's exact test (Fig <xref rid="fig1" ref-type="fig">1</xref>, Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>). The Kaplan-Meier time-to-event plot was created using the ICD10 datasets, and cases were censored for CRC diagnosis and age at testing, which was used as a proxy for age at onset of CRC. Data were plotted and analyzed by the log-rank test using SRPlot.<sup><xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b14" ref-type="bibr">14</xref></sup></p><table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE 1.</label><caption><p><italic toggle="yes">RPS20</italic> Cohort Characteristics and Cancer Associations Versus Wild-Type</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" colspan="1">Characteristic</th><th align="center" colspan="2" rowspan="1">No. (%)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">RPS20 </italic>pLoF <italic toggle="yes">v</italic> WT</th><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th align="center" rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> pLOF</th><th align="center" rowspan="1" colspan="1">WT-Curated</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">19,810</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Sex, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Female</td><td align="char" char="(" rowspan="1" colspan="1">22 (61.1)</td><td align="char" char="(" rowspan="1" colspan="1">16,600 (83.8)</td><td align="char" char="(" rowspan="1" colspan="1">0.266 (0.133 to 0.542)</td><td rowspan="1" colspan="1">.0001</td></tr><tr><td rowspan="1" colspan="1">&#8195;Male</td><td align="char" char="(" rowspan="1" colspan="1">14 (38.9)</td><td align="char" char="(" rowspan="1" colspan="1">3,209 (16.2)</td><td align="char" char="(" rowspan="1" colspan="1">3.292 (1.556 to 6.737)</td><td rowspan="1" colspan="1">.0009</td></tr><tr><td rowspan="1" colspan="1">&#8195;Unknown</td><td align="char" char="(" rowspan="1" colspan="1">0 (0)</td><td align="char" char="(" rowspan="1" colspan="1">1 (0.005)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Ethnicity, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;White</td><td align="char" char="(" rowspan="1" colspan="1">20 (55.6)</td><td align="char" char="(" rowspan="1" colspan="1">10,377 (52.4)</td><td align="char" char="(" rowspan="1" colspan="1">1.136 (0.559 to 2.346)</td><td rowspan="1" colspan="1">.741</td></tr><tr><td rowspan="1" colspan="1">&#8195;African American</td><td align="char" char="(" rowspan="1" colspan="1">3 (8.3)</td><td align="char" char="(" rowspan="1" colspan="1">1,715 (8.7)</td><td align="char" char="(" rowspan="1" colspan="1">0.959 (0.188 to 3.062)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hispanic</td><td align="char" char="(" rowspan="1" colspan="1">2 (5.6)</td><td align="char" char="(" rowspan="1" colspan="1">1,016 (5.1)</td><td align="char" char="(" rowspan="1" colspan="1">1.088 (0.261 to 4.536)</td><td rowspan="1" colspan="1">.908</td></tr><tr><td rowspan="1" colspan="1">&#8195;Asian</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">689 (3.5)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#8195;Ashkenazi Jewish</td><td align="center" rowspan="1" colspan="1">0</td><td align="char" char="(" rowspan="1" colspan="1">593 (3.0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#8195;Mixed ethnicity/Other/unknown</td><td align="char" char="(" rowspan="1" colspan="1">11 (30.5)</td><td align="char" char="(" rowspan="1" colspan="1">5,420 (27.4)</td><td align="char" char="(" rowspan="1" colspan="1">1.168 (0.518 to 2.463)</td><td rowspan="1" colspan="1">.709</td></tr><tr><td rowspan="1" colspan="1">Age, years, median (IQR)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Age at testing</td><td align="char" char="(" rowspan="1" colspan="1">50 (37.5-62)</td><td align="char" char="(" rowspan="1" colspan="1">52 (42-62)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">.331</td></tr><tr><td rowspan="1" colspan="1">&#8195;Age at first cancer</td><td align="char" char="(" rowspan="1" colspan="1">48 (39-58.5)</td><td align="char" char="(" rowspan="1" colspan="1">53 (44-63)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">.020</td></tr><tr><td rowspan="1" colspan="1">&#8195;Age at first CRC</td><td align="char" char="(" rowspan="1" colspan="1">50 (40-58)</td><td align="char" char="(" rowspan="1" colspan="1">50 (44-60)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">.227</td></tr><tr><td rowspan="1" colspan="1">Any cancer, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">30 (83.33)</td><td align="char" char="(" rowspan="1" colspan="1">10,662 (53.82)</td><td align="char" char="(" rowspan="3" colspan="1">4.024 (1.647 to 11.835)</td><td rowspan="3" colspan="1">.0006</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">6 (16.67)</td><td align="char" char="(" rowspan="1" colspan="1">8,582 (43.32)</td></tr><tr><td rowspan="1" colspan="1">&#8195;Not provided</td><td align="char" char="(" rowspan="1" colspan="1">0 (0)</td><td align="char" char="(" rowspan="1" colspan="1">566 (2.86)</td></tr><tr><td rowspan="1" colspan="1">&gt;1 cancer, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">9 (25.00)</td><td align="char" char="(" rowspan="1" colspan="1">2,174 (10.97)</td><td align="char" char="(" rowspan="2" colspan="1">2.704 (1.117 to 5.933)</td><td rowspan="2" colspan="1">.0139</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">27 (75.00)</td><td align="char" char="(" rowspan="1" colspan="1">17,636 (89.03)</td></tr><tr><td rowspan="1" colspan="1">Polyps, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">9 (25.00)</td><td align="char" char="(" rowspan="1" colspan="1">2,575 (13.00)</td><td align="char" char="(" rowspan="2" colspan="1">2.231 (0.922 to 4.894)</td><td rowspan="2" colspan="1">.044</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">27 (75.00)</td><td align="char" char="(" rowspan="1" colspan="1">17,235 (87.00)</td></tr><tr><td rowspan="1" colspan="1">CRC, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">23 (63.89)</td><td align="char" char="(" rowspan="1" colspan="1">910 (4.59)</td><td align="char" char="(" rowspan="2" colspan="1">36.721 (17.779 to 79.323)</td><td rowspan="2" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">13 (36.11)</td><td align="char" char="(" rowspan="1" colspan="1">18,900 (95.41)</td></tr><tr><td rowspan="1" colspan="1">Multiple CRCs, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">7 (19.44)</td><td align="char" char="(" rowspan="1" colspan="1">80 (0.40)</td><td align="char" char="(" rowspan="2" colspan="1">59.412 (21.336 to 144.014)</td><td rowspan="2" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">29 (80.56)</td><td align="char" char="(" rowspan="1" colspan="1">19,730 (99.60)</td></tr><tr><td rowspan="1" colspan="1">Signet ring CRC, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">4<xref rid="tblfn4" ref-type="table-fn"><sup>a</sup></xref> (11.11)</td><td align="char" char="(" rowspan="1" colspan="1">11 (0.06)</td><td align="char" char="(" rowspan="2" colspan="1">223.56 (49.263 to 799.09)</td><td rowspan="2" colspan="1">&lt;.001</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">32 (88.89)</td><td align="char" char="(" rowspan="1" colspan="1">19,799 (99.94)</td></tr><tr><td rowspan="1" colspan="1">Female breast, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">5 (22.73)</td><td align="char" char="(" rowspan="1" colspan="1">6,401 (38.56)</td><td align="char" char="(" rowspan="2" colspan="1">0.469 (0.135 to 1.324)</td><td rowspan="2" colspan="1">.187</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">17 (77.27)</td><td align="char" char="(" rowspan="1" colspan="1">10,199 (61.44)</td></tr><tr><td rowspan="1" colspan="1">Anal, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">1 (2.78)</td><td align="char" char="(" rowspan="1" colspan="1">11 (0.06)</td><td align="char" char="(" rowspan="2" colspan="1">51.252 (1.162 to 370.15)</td><td rowspan="2" colspan="1">.022</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">35 (97.22)</td><td align="char" char="(" rowspan="1" colspan="1">19,799 (99.94)</td></tr><tr><td rowspan="1" colspan="1">Appendiceal, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">1 (2.78)</td><td align="char" char="(" rowspan="1" colspan="1">55 (0.28)</td><td align="char" char="(" rowspan="2" colspan="1">10.259 (0.248 to 63.308)</td><td rowspan="2" colspan="1">.097</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">35 (97.22)</td><td align="char" char="(" rowspan="1" colspan="1">19,755 (99.72)</td></tr><tr><td rowspan="1" colspan="1">Bladder, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">1 (2.78)</td><td align="char" char="(" rowspan="1" colspan="1">107 (0.54)</td><td align="char" char="(" rowspan="2" colspan="1">5.261 (0.128 to 31.896)</td><td rowspan="2" colspan="1">.178</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">35 (97.22)</td><td align="char" char="(" rowspan="1" colspan="1">19,703 (99.46)</td></tr><tr><td rowspan="1" colspan="1">Basal cell, No. (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Yes</td><td align="char" char="(" rowspan="1" colspan="1">1 (2.78)</td><td align="char" char="(" rowspan="1" colspan="1">587 (2.96)</td><td align="char" char="(" rowspan="2" colspan="1">0.936 (0.023 to 5.587)</td><td rowspan="2" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">&#8195;No</td><td align="char" char="(" rowspan="1" colspan="1">35 (97.22)</td><td align="char" char="(" rowspan="1" colspan="1">19,223 (97.04)</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>Abbreviations: CRC, colorectal cancer; NA, not applicable or unable to be calculated; OR, odds ratio; pLoF, putative loss-of-function; WT, wild-type.</p></fn><fn fn-type="other" id="tblfn4"><label>
<sup>a</sup>
</label><p>One individual had two primary CRCs that both had signet ring CRC so although four individuals had this, there are five tumors described with signet ring pathology.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="figure" id="fig1" orientation="portrait"><label>FIG 1.</label><caption><p><italic toggle="yes">RPS20</italic> pLoF heterozygotes are characterized by early-onset and multiple primary CRC exceeding that of <italic toggle="yes">MLH1</italic> heterozygotes. (A) Swimmer plot showing individual proband characteristics (P1-P36) until age at genetic testing. Deidentified proband number, the identified <italic toggle="yes">RPS20</italic> heterozygous variant identified and the MMR status, if applicable, is included in the arrow. Proband sex at birth is indicated by color, with pink as female and blue as male. Recurrent variants are colored with green text. Cancer diagnoses are denoted by unique shapes per the key, and multiple diagnosis, when applicable, are indicated with a number within the relevant cancer shape. The presence and number of colonic polyps and first-degree relatives diagnosed with CRC are indicated at the far right with the number of polyps or relatives included in parentheses. Cases are grouped by variant type which is indicated at the far left; (B) forest plot comparing the prevalence of CRC in individuals with pLoF in <italic toggle="yes">RPS20</italic> and LP/P in LS genes <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, and <italic toggle="yes">PMS2</italic> compared with a similarly ascertained WT cohort of individuals with no VUS/LP/P identified via pan-cancer MGPT (up to 85 genes). All LS genes (used as positive control cohorts) show a significantly higher prevalence of CRC compared with WT. Individuals with pLoF in <italic toggle="yes">RPS20</italic> also show a significantly higher prevalence of CRC compared with WT and at least 2-fold higher than <italic toggle="yes">MLH1</italic> (OR of 45.3 <italic toggle="yes">v</italic> 19.3). (C) Kaplan-Meier time-to-event plot censoring at CRC diagnosis at age at testing among heterozygotes for <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, <italic toggle="yes">PMS2</italic>, and <italic toggle="yes">RPS20</italic>. Affectation status was derived from ICD10 codes (<xref rid="app1" ref-type="app">Appendix 1</xref>, Appendix Table A<xref rid="tblA1" ref-type="table">1</xref>). 95% CI are shaded. <sup>a</sup>Individual P7 is also heterozygous for an <italic toggle="yes">ATM</italic> pathogenic variant, a gene with limited evidence for CRC predisposition. <sup>b</sup>Indicates that the tumor is positive for MLH1 promoter hypermethylation. CRC, colorectal cancer; dMMR, deficient MMR; FDR, first-degree relative; LP, likely pathogenic; LS, Lynch syndrome; MGPT, multigene panel testing; MMR, mismatch repair; N, no; NOS, not otherwise specified; NP, not provided; P, pathogenic; pLoF, putative loss-of-function; pMMR, proficient MMR; VUS, variant of uncertain significance; WT, wildtype; Y, yes.</p></caption><graphic position="float" orientation="portrait" xlink:href="po-9-e2500214-g001.jpg"/></fig></sec><sec><title>Gene-Disease Validity Assessment</title><p>GDV analysis was completed using an evidence-based scoring framework,<sup><xref rid="b15" ref-type="bibr">15</xref></sup> with current scoring methods detailed in Appendix Tables A<xref rid="tblA1" ref-type="table">1</xref> and A<xref rid="tblA3" ref-type="table">3</xref>.</p></sec><sec><title>Ethics Approval and Consent to Participate</title><p>The WCG Institutional Review Board determined the study to be exempt from the Office for Human Research Protections Regulations for the Protection of Human Subjects (45 CFR 46) under category 4. Retrospective data analysis of deidentified data exempted the study from the requirement to receive consent from patients.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title><italic toggle="yes">RPS20</italic> pLoF Cohort Characteristics</title><p>A total of 36 of 950,000 individuals had one of 28 unique pLoF variants in <italic toggle="yes">RPS20</italic>, representing an overall frequency of 0.004%. Among the identified variants are three different start-loss variants (individuals P1-P3), 18 nonsense or frameshift variants causing premature termination (individuals P4 through P24), and seven canonical splicing variants (individuals P25 through P36; Fig <xref rid="fig1" ref-type="fig">1</xref>A). Notably, several variants were recurrent in this cohort: two individuals were heterozygous for each <italic toggle="yes">RPS20</italic> c.10A&gt;T (P.K4*), <italic toggle="yes">RPS20</italic> c.122delG (p.R41Kfs*10), <italic toggle="yes">RPS20</italic> c.298C&gt;T (<italic toggle="yes">p</italic>.Q100*), and <italic toggle="yes">RPS20</italic> c.104-1G&gt;A. Three individuals were heterozygous for each <italic toggle="yes">RPS20</italic> c.3+1G&gt;A and <italic toggle="yes">RPS20</italic> c.104-2A&gt;G. Canonical splicing variants were predicted to lead to premature termination after review of RNA capture-seq (data not shown). One individual was also heterozygous for another PV in <italic toggle="yes">ATM</italic> (Fig <xref rid="fig1" ref-type="fig">1</xref>A, individual P7).</p><p>Within the <italic toggle="yes">RPS20</italic> cohort, a majority self-identified as female at birth (61.1%), which is statistically fewer compared with the WT-curated cohort (83.8%, Table <xref rid="tbl1" ref-type="table">1</xref>). The self-reported ethnic characteristics were similar between the <italic toggle="yes">RPS20</italic> and WT-curated cohorts. Although the age at testing and age at first CRC diagnosis were similar between them, there was a statistically younger median age at first cancer within the <italic toggle="yes">RPS20</italic> cohort compared with the WT-curated cohort (<italic toggle="yes">RPS20</italic> 48 years <italic toggle="yes">v</italic> WT-curated 53 years, <italic toggle="yes">P</italic> = .020). There was also a statistically higher prevalence of having more than one primary cancer diagnosis in the <italic toggle="yes">RPS20</italic> cohort (<italic toggle="yes">RPS20</italic> = 25% <italic toggle="yes">v</italic> WT-curated = 10.97%, <italic toggle="yes">P</italic> = &lt;.001). Consistent with observational findings from previous studies, individuals in the <italic toggle="yes">RPS20</italic> cohort reported polyps, and the frequency of this was statistically higher than that of the WT-curated cohort (<italic toggle="yes">RPS20</italic> = 25% <italic toggle="yes">v</italic> WT-curated = 13%, <italic toggle="yes">P</italic> = .044). A total of 8 of 9 (88.9%) individuals reported a total polyp count of &lt;10. One individual (P16) reported 50-100 polyps. A total of 5 of 9 individuals reported pathology, all of which were adenomatous polyps.</p><p>Three clinical features stand out as dramatically more frequent in the <italic toggle="yes">RPS20</italic> cohort relative to the WT-curated cohort: The prevalence of CRC in the <italic toggle="yes">RPS20</italic> cohort was 63.9%, whereas the prevalence in the WT-curated cohort was only 4.59% (<italic toggle="yes">P</italic> = &lt;.001). In addition, 19.44% of individuals in the <italic toggle="yes">RPS20</italic> cohort reported multiple primary CRCs versus 0.40% of the WT-curated cohort (<italic toggle="yes">P</italic> &lt; .001). Five individuals (13.9%) reported two primary CRCs, whereas one individual (2.8%) reported three primary CRCs (Fig <xref rid="fig1" ref-type="fig">1</xref>, individuals P3, P6, P24, P31, and P35 and individual P27, respectively).</p><p>Among the 23 (63.9%) individuals in the <italic toggle="yes">RPS20</italic> cohort who reported CRC, 14 also submitted tumor testing information for mismatch repair deficiency/mismatch repair proficiency (pMMR) for LS. The majority of these individuals had pMMR CRCs. Three individuals (2.1%) had abnormal immunohistochemistry (IHC) with absent MLH1/PMS2 (one of which was confirmed to have <italic toggle="yes">MLH1</italic> promoter hypermethylation), and one individual reported abnormal IHC but with no details (Fig <xref rid="fig1" ref-type="fig">1</xref>). Finally, four individuals (11.1%) in the <italic toggle="yes">RPS20</italic> cohort reported signet ring cell (SRC) pathology for their CRCs, whereas only 0.06% of the WT-curated cohort did (<italic toggle="yes">P</italic> &lt; .001). Of note, one individual had two CRCs with SRC pathology for a total of five tumors (Table <xref rid="tbl1" ref-type="table">1</xref>).</p><p>Other cancer diagnoses included 22.7% (5 of 22) with female breast cancer, which was not statistically different from the WT-curated cohort (38.56%, <italic toggle="yes">P</italic> = .187). Of the 42 reported cancers, there was one report each for anal, appendiceal, bladder, and basal cell carcinoma (2.4% each). When compared with the frequency in the WT-curated cohort, only the anal cancer was statistically significant (<italic toggle="yes">RPS20</italic> = 2.8% <italic toggle="yes">v</italic> WT-curated = 0.06%, <italic toggle="yes">P</italic> = .022).</p></sec><sec><title>Comparison of <italic toggle="yes">RPS20</italic> pLoF With LS Cohorts</title><p>The observation of a highly statistically significant frequency of CRC relative to the WT-curated cohort warrants benchmarking to other CRC predisposition genes that have clinical management guidelines. Thus, the <italic toggle="yes">RPS20</italic> pLoF cohort was compared with a similarly ascertained LS cohort from this laboratory. To maximize the number of individuals and to reduce bias that may be built into selective curation of cases and changes in ascertainment bias over time, a cohort of consecutive cases with limited available information was built. Information documented included sex at birth, ICD10 codes corresponding to CRC, and age at testing (<xref rid="app1" ref-type="app">Appendix 1</xref>). A total of 33 of 36 individuals with <italic toggle="yes">RPS20</italic> pLoF were identified in this ICD10 data set. Three individuals from the curated data set were absent because of date- and/or test-inclusion differences. In addition, two individuals noted to have CRC did not have corresponding ICD10 codes for CRC, which is within the rate of error based on sensitivity analysis for the ICD10 data set (Methods).</p><p>Odds ratios (ORs) were calculated relative to the WT-ICD10 cohort of individuals without reported VUS/LP/P variants. The ICD10-<italic toggle="yes">RPS20</italic> pLoF and ICD10-Lynch cohorts all had significantly higher odds of CRC compared with WT-ICD10 and reflected the current understanding of the magnitude of CRC penetrance among the LS genes (<italic toggle="yes">RPS20:</italic> OR = 45.3 &gt; <italic toggle="yes">MLH1</italic>: OR = 16.9 &gt; <italic toggle="yes">MSH2</italic>: OR = 11.5 &gt; <italic toggle="yes">MSH6</italic>: OR = 4.6 &gt; <italic toggle="yes">PMS2:</italic> OR = 3.7). Critically, the ICD10-<italic toggle="yes">RPS20</italic> cohort had statistically significantly higher odds of CRC than the ICD10-<italic toggle="yes">MLH1</italic> cohort and the upper bound 95% confidence interval for ICD10-<italic toggle="yes">MLH1</italic> did not overlap with the lower bound for ICD10-<italic toggle="yes">RPS20</italic> (Fig <xref rid="fig1" ref-type="fig">1</xref>B, Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>). By contrast, the ICD10-<italic toggle="yes">RPS20</italic> missense cohort did not have statistically significant odds of CRC compared with the WT-ICD10 cohort. Stratification of missense variants with BayesDel score 0.41-0.493 revealed the highest enrichment of CRC compared with ICD10-WT (OR, 1.85 [95% CI, 0.81 to 4.24]; <italic toggle="yes">P</italic> value .14) but was still not statistically significant. No missense variants had a BayesDel score higher than 0.493 (Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>).</p><p>In evaluating the age at testing among the ICD10-<italic toggle="yes">RPS20</italic> and ICD10-Lynch cohorts using Kaplan-Meier analyses censored for CRC (per ICD10 code), as a group, individuals with <italic toggle="yes">RPS20</italic> pLoF alterations were censored more frequently and at earlier ages than individuals with LS, suggesting an earlier age at onset for the <italic toggle="yes">RPS20</italic> pLoF cohort; individuals with LS, again, reflected the current understanding with respect to the magnitude of penetrance and age at onset for the different genes, with <italic toggle="yes">MLH1</italic>-related LS having the highest risk and earliest age at onset and <italic toggle="yes">PMS2</italic>-related LS having the lowest incidence and age at onset of CRC (Fig <xref rid="fig1" ref-type="fig">1</xref>C).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Identification of genes involved in hereditary CRC is an important ongoing effort as less than a quarter of familial cases are explained by genetic causes.<sup><xref rid="b1" ref-type="bibr">1</xref></sup> A proportion of this missing heritability may be explained by non-Mendelian genetics or nongenetic factors.<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b16" ref-type="bibr">16</xref></sup> Alternatively, additional Mendelian causes may exist but have not yet been uncovered for various reasons.<sup><xref rid="b17" ref-type="bibr">17</xref></sup> The discovery of<italic toggle="yes"> RPS20</italic>'s putative association with hereditary CRC was latent in this modern era of cancer genetic testing, which is surprising given the very high crude penetrance revealed in this study. This is likely attributable to the high level of constraint against LoF in this gene, with very few individuals harboring pLoF in the literature (four families),<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b5" ref-type="bibr">5</xref></sup> large general population databases such as gnomAD (pLI = 0.97, observed/expected = 0.15 (0.06-0.48)),<sup><xref rid="b18" ref-type="bibr">18</xref></sup> and in clinical cohorts such as described herein (frequency of 0.004%), where the frequency is 100-fold rarer than <italic toggle="yes">MLH1</italic>-associated LS (0.11%). Until now, the reinforcement of the association between <italic toggle="yes">RPS20</italic> and CRC and the evaluation of additional associated features, including risk, have been impossible.</p><p>To our knowledge, this is the largest reported series of individuals with pLoF in <italic toggle="yes">RPS20</italic> and represents a 9-fold increased contribution to currently published pLoF cases in the literature, allowing for comprehensive characterization and quantification of <italic toggle="yes">RPS20</italic>-related cancer predisposition. While previous publications have suggested an association with hereditary CRC, data are from very few cases and from cohorts ascertained for hereditary CRC, which can bias results and artificially inflate penetrance. This study uses a genotype-first approach in a diverse clinical MGPT cancer cohort referred for multiple tumor indications and provides a more accurate crude penetrance for CRC. The results show that even in a cohort not specifically ascertained for hereditary CRC, the odds of being diagnosed with CRC in individuals heterozygous for pLoF in <italic toggle="yes">RPS20</italic> are dramatically higher than that in a similarly ascertained WT cohort (OR, 45.3-fold).</p><p>In total, with the patients in this study plus those from the literature, there are 54 individuals from 40 families with pLoF in <italic toggle="yes">RPS20</italic> (Appendix Table A<xref rid="tblA4" ref-type="table">4</xref>). Of note, two additional literature-based familial CRC cases harbored missense variants in <italic toggle="yes">RPS20</italic> (detailed in Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>) with an unknown functional impact and were excluded from these pLoF totals.<sup><xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b5" ref-type="bibr">5</xref></sup> The missense variant analyses in this study showed no significantly increased odds of CRC (OR, 0.95 [95% CI, 0.55 to 1.51]; <italic toggle="yes">P</italic> = .91), further supporting a mechanism of disease as loss of function predominantly because of truncations subject to nonsense-mediated decay. Additional studies are warranted to elucidate the pathogenicity of identified missense variants in clinically suspicious families. Although the published studies look at prevalence and age at onset among members of three pLoF families, it is important to note that CRC prevalence was higher and age at onset was younger in this study of unrelated individuals relative to the published literature. This further reinforces these initial findings and represents a major step forward in solidifying the GDV between <italic toggle="yes">RPS20</italic> and early-onset CRC. Combining these genotype-first cohort results with the previously published families elevated the GDV score from limited to moderate for <italic toggle="yes">RPS20</italic>-related CRC predisposition, allowing for the classification of variants as LP/P. Additional case reports and/or cosegregation analyses would result in a definitive GDV classification.</p><p>This large cohort allows, for the first time, the statistical comparison of individuals with <italic toggle="yes">RPS20</italic> pLoF with control cohorts. Both the <italic toggle="yes">RPS20</italic> and WT-curated cohorts had similar ethnic distributions, and although each had a majority of female probands, the <italic toggle="yes">RPS20</italic> cohort showed a significantly higher proportion of males. This is likely due to referral bias within this clinical cohort, where early-onset female breast cancer is the most frequent primary indication for MGPT. Overall, compared with WT, the <italic toggle="yes">RPS20</italic> cohort was statistically enriched for cancer diagnoses of any type (83.33% <italic toggle="yes">RPS20 v</italic> 53.82% WT) with earlier age at first cancer diagnosis (48 years <italic toggle="yes">RPS20 v</italic> 53 years WT). These individuals also more commonly had multiple primary cancer diagnoses (25.00% <italic toggle="yes">RPS20 v</italic> 10.97% WT) and more commonly had polyps (25.00% <italic toggle="yes">RPS20 v</italic> 13.00% WT). Finally, the <italic toggle="yes">RPS20</italic> cohort was dramatically enriched for CRC (63.9% <italic toggle="yes">RPS20 v</italic> 4.59% WT), multiple primary CRCs (19.44% <italic toggle="yes">RPS20 v</italic> 0.40% WT), and CRC with SRC pathology, a rare subtype of CRC that encompasses only 1%-2% of all CRC diagnoses<sup><xref rid="b19" ref-type="bibr">19</xref></sup> (11.11% <italic toggle="yes">RPS20 v</italic> 0.06% WT). In addition, based on observational data, CRC was overwhelmingly pMMR. This finding is consistent with previous reports and emphasizes the distinction of <italic toggle="yes">RPS20</italic>-related CRC from LS-related CRC.</p><p>Although 25% (9 of 36) of our probands reported polyps, which was statistically higher than our WT-curated cohort (<italic toggle="yes">P</italic> = .044), 88.9% (8 of 9) had fewer than 10 polyps, supporting that <italic toggle="yes">RPS20</italic> confers risk for nonpolyposis CRC. Reported polyps had adenomatous pathology; no previous pathology related to polyps has been published.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> Proband P16 (reporting 50-100 cumulative polyps) was subjected to additional analyses (sensitive bioinformatics pipeline review of NGS and RNA analyses) to rule out mosaic or deep intronic findings in polyposis genes, with no additional variants detected. However, we cannot exclude another etiology for this proband's polyposis.</p><p>Extracolonic cancers in the <italic toggle="yes">RPS20</italic> cohort were rare; however, the presence of anal cancer (a rare cancer type) was enriched compared with WT (2.8% <italic toggle="yes">RPS20 v</italic> 0.06% WT). Given that this was a single case, further studies are necessary to demonstrate associations with anal cancer and the other extracolonic cancers that were observed. Notably, the observation of <italic toggle="yes">RPS20</italic> pLoF variants in very few people <italic toggle="yes">without</italic> CRC underscores the high crude penetrance for this GDR. The significance of SRC CRC is also a novel finding not previously reported in association with <italic toggle="yes">RPS20</italic>.<sup><xref rid="b2" ref-type="bibr">2</xref>-<xref rid="b5" ref-type="bibr">5</xref></sup></p><p>A limitation of this study is the lack of available tumor sequencing data in individuals with germline pLoF variants in <italic toggle="yes">RPS20</italic>. Future studies in this area could shed light on whether biallelic loss of <italic toggle="yes">RPS20</italic> or other mutational features are seen in <italic toggle="yes">RPS20</italic> heterozygotes. In addition, data regarding colonoscopy and pathology results for many probands were not available and therefore do not allow us to draw strong conclusions on the polyp phenotype in this population.</p><p>The identification of high penetrance supports implementing clinical management for individuals with <italic toggle="yes">RPS20</italic> pLoF variants. To support the level of management that may be needed, a comparison with <italic toggle="yes">MLH1-</italic>associated LS was drawn. There is two-fold increased odds for CRC in individuals with <italic toggle="yes">RPS20</italic> pLoF over individuals with <italic toggle="yes">MLH1</italic>-associated LS, and notably, the upper and lower 95% confidence intervals do not overlap (OR, 45.3 <italic toggle="yes">RPS20</italic>-ICD10 <italic toggle="yes">v</italic> OR, 16.9 WT-ICD10, Fig <xref rid="fig1" ref-type="fig">1</xref>B, Appendix Table A<xref rid="tblA2" ref-type="table">2</xref>). This finding supports <italic toggle="yes">RPS20</italic> as a more penetrant CRC predisposition gene relative to <italic toggle="yes">MLH1</italic>-related LS. While the relative enrichment of CRC in <italic toggle="yes">RPS20</italic> and <italic toggle="yes">MLH1</italic> should be replicated in additional cohorts, the increase shown in <italic toggle="yes">RPS20</italic> demonstrates that CRC management should at least mirror that of <italic toggle="yes">MLH1</italic>-related LS.<sup><xref rid="b20" ref-type="bibr">20</xref></sup></p><p>In conclusion, <italic toggle="yes">RPS20</italic> is associated with an early-onset, highly penetrant, MMR-proficient CRC predisposition caused by heterozygous pLoF. Multiple primary CRCs and SRC pathology are likely part of the spectrum but should be replicated in other cohorts. Because the prevalence and age at onset of CRC in <italic toggle="yes">RPS20</italic> pLoF heterozygotes are similar to or worse than those of <italic toggle="yes">MLH1</italic> heterozygotes, these data support implementation of management guidelines similar to those for <italic toggle="yes">MLH1</italic>-related CRC. Testing of <italic toggle="yes">RPS20</italic> is warranted in individuals with a significant personal and/or family history of early-onset CRC, especially if MMR proficient and/or with SRC pathology. Finally, because of this study, the GDV for <italic toggle="yes">RPS20</italic>-related CRC predisposition can now be considered at least moderate, and variants are eligible to be classified as LP/P, paving the way for appropriate clinical management as proposed.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>We would like to thank Cynthia Martinez, BS, and Lily Hoang, BA, for their contributions to data acquisition for this case series, and Brooklynn Gasser, for her analysis for age at testing versus age at diagnosis for the ICD10 cohort.</p></ack><sec sec-type="data-availability"><title>DATA SHARING STATEMENT</title><p>Ambry Genetics supports open data sharing. Data that are not included in this published article will be made available upon request except detailed patient data that would compromise HIPAA-compliant safeguards applied to protect patient privacy. Internal GDV scores are submitted to the Gene Curation Coalition Database (GenCC DB; <ext-link xlink:href="https://thegencc.org/" ext-link-type="uri">https://thegencc.org/</ext-link>), and variant classifications are submitted to ClinVar (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>).</p></sec><sec sec-type="contributed"><title>AUTHOR CONTRIBUTIONS</title><p><bold>Conception and design:</bold> Jennifer Herrera-Mullar, Ashley PL Marsh, Emily Kudalkar, Marcy E. Richardson</p><p><bold>Administrative support:</bold> Marcy E. Richardson</p><p><bold>Collection and assembly of data:</bold> Jennifer Herrera-Mullar, Cassidy Carraway, Ashley P.L. Marsh, Marcy E. Richardson</p><p><bold>Data analysis and interpretation:</bold> Jennifer Herrera-Mullar, Ashley P.L. Marsh, Felicia Hernandez, Emily Kudalkar, Marcy E. Richardson</p><p><bold>Manuscript writing:</bold> All authors</p><p><bold>Final approval of manuscript:</bold> All authors</p><p><bold>Accountable for all aspects of the work:</bold> All authors</p></sec><sec sec-type="COI-statement"><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/po/author-center" ext-link-type="uri">ascopubs.org/po/author-center</ext-link>.</p><p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p><fn-group content-type="COI-statement"><fn id="con1" specific-use="COI-statement" fn-type="other"><p>
<bold>Jennifer Herrera-Mullar</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn id="con2" specific-use="COI-statement" fn-type="other"><p>
<bold>Cassidy Carraway</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn id="con3" specific-use="COI-statement" fn-type="other"><p>
<bold>Ashley P.L. Marsh</bold>
</p><p><bold>Employment:</bold> Ambry Genetics Corporation</p></fn><fn id="con4" specific-use="COI-statement" fn-type="other"><p>
<bold>Felicia Hernandez</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn id="con5" specific-use="COI-statement" fn-type="other"><p>
<bold>Emily Kudalkar</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn id="con6" specific-use="COI-statement" fn-type="other"><p>
<bold>Marcy E. Richardson</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></sec><notes><fn-group content-type="COI-statement"><fn specific-use="COI-statement" fn-type="other"><p>
<bold>Jennifer Herrera-Mullar</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn specific-use="COI-statement" fn-type="other"><p>
<bold>Cassidy Carraway</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn specific-use="COI-statement" fn-type="other"><p>
<bold>Ashley P.L. Marsh</bold>
</p><p><bold>Employment:</bold> Ambry Genetics Corporation</p></fn><fn specific-use="COI-statement" fn-type="other"><p>
<bold>Felicia Hernandez</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn specific-use="COI-statement" fn-type="other"><p>
<bold>Emily Kudalkar</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p></fn><fn specific-use="COI-statement" fn-type="other"><p>
<bold>Marcy E. Richardson</bold>
</p><p><bold>Employment:</bold> Ambry Genetics</p><p>No other potential conflicts of interest were reported.</p></fn></fn-group></notes><app-group><app id="app1"><title>APPENDIX 1. SUPPLEMENTAL METHODS</title><p><italic toggle="yes">International Classification of Diseases Codes-10</italic> Datasets: codes corresponding to a colorectal cancer (CRC) diagnosis included the following: <list list-type="simple"><list-item><p>C18.0&#8212;Malignant neoplasm of cecum;</p></list-item><list-item><p>C18.2&#8212;Malignant neoplasm of ascending colon;</p></list-item><list-item><p>C18.3&#8212;Malignant neoplasm of hepatic flexure;</p></list-item><list-item><p>C18.4&#8212;Malignant neoplasm of transverse colon;</p></list-item><list-item><p>C18.5&#8212;Malignant neoplasm of splenic flexure;</p></list-item><list-item><p>C18.6&#8212;Malignant neoplasm of descending colon;</p></list-item><list-item><p>C18.7&#8212;Malignant neoplasm of sigmoid colon;</p></list-item><list-item><p>C18.8&#8212;Malignant neoplasm of overlapping sites of colon;</p></list-item><list-item><p>C18.9&#8212;Malignant neoplasm of colon, unspecified;</p></list-item><list-item><p>C19&#8212;Malignant neoplasm of rectosigmoid junction;</p></list-item><list-item><p>C20&#8212;Malignant neoplasm of rectum;</p></list-item><list-item><p>C21.0&#8212;Malignant neoplasm of anus, unspecified;</p></list-item><list-item><p>C21.1&#8212;Malignant neoplasm of anal canal;</p></list-item><list-item><p>C21.2&#8212;Malignant neoplasm of cloacogenic zone;</p></list-item><list-item><p>C21.8&#8212;Malignant neoplasm of overlapping sites of rectum, anus, and anal canal;</p></list-item><list-item><p>Z85.00&#8212;Personal history of malignant neoplasm of unspecified digestive organ;</p></list-item><list-item><p>Z85.03&#8212;Personal history of malignant neoplasm of large intestine;</p></list-item><list-item><p>Z85.04&#8212;Personal history of malignant neoplasm of rectum, rectosigmoid junction, and</p></list-item></list></p><table-wrap position="anchor" id="tblA1" orientation="portrait"><label>TABLE A1.</label><caption><p>GDV Scoring</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th colspan="4" rowspan="1">Before <italic toggle="yes">RPS20</italic> pLoF Cohort Analysis</th></tr><tr><th rowspan="1" colspan="1">Evidence Type</th><th align="center" rowspan="1" colspan="1">Information Source</th><th align="center" rowspan="1" colspan="1">Points</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Case level</td><td rowspan="1" colspan="1">PMIDs 24941021, 27713038, 32424863, 33193653</td><td align="center" rowspan="1" colspan="1">5.4</td><td align="center" rowspan="1" colspan="1">5.4</td></tr><tr><td rowspan="1" colspan="1">Experimental</td><td rowspan="1" colspan="1">PMIDs 35682850, 38002277</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td colspan="4" rowspan="1">Total: 6.4 (limited GDV)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th colspan="4" rowspan="1">Including Probands From the <italic toggle="yes">RPS20</italic> pLoF Cohort</th></tr><tr><th rowspan="1" colspan="1">Evidence Type</th><th align="center" rowspan="1" colspan="1">Information Source</th><th align="center" rowspan="1" colspan="1">Points</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Case level</td><td rowspan="1" colspan="1">PMIDs 24941021, 27713038, 32424863, 33193653, 39920491</td><td align="center" rowspan="1" colspan="1">6.7</td><td align="center" rowspan="1" colspan="1">10.7</td></tr><tr><td rowspan="1" colspan="1">Case-control</td><td rowspan="1" colspan="1">Internal probands <italic toggle="yes">v</italic> WT-curated</td><td align="center" rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Experimental</td><td rowspan="1" colspan="1">PMIDs 35682850, 38002277, 38290548</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td colspan="4" rowspan="1">Total: 12.7 (moderate GDV)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1">GDV</th><th align="center" rowspan="1" colspan="1">Points</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Disputed</td><td align="center" rowspan="1" colspan="1">&lt;0</td></tr><tr><td rowspan="1" colspan="1">No reported evidence</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Limited</td><td align="center" rowspan="1" colspan="1">0.1-7.9</td></tr><tr><td rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">8.0-12.9</td></tr><tr><td rowspan="1" colspan="1">Strong</td><td align="center" rowspan="1" colspan="1">13.0-16.9</td></tr><tr><td rowspan="1" colspan="1">Definitive</td><td align="center" rowspan="1" colspan="1">17+</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>Abbreviations: GDV, gene-disease validity; WT, wildtype.</p></fn></table-wrap-foot></table-wrap><table-wrap position="anchor" id="tblA2" orientation="portrait"><label>TABLE A2.</label><caption><p>Prevalence of CRC (obtained from ICD10 data) in All Cohorts With Comparison With the Wild-Type Cohort</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1">Total</th><th align="center" rowspan="1" colspan="1">CRC Yes, No. (%)</th><th align="center" rowspan="1" colspan="1">CRC, No (%)</th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1"><italic toggle="yes">MLH1</italic> (LP/P)</td><td align="center" rowspan="1" colspan="1">1,077</td><td align="char" char="(" rowspan="1" colspan="1">425 (39.5)</td><td align="char" char="(" rowspan="1" colspan="1">652 (60.5)</td><td align="char" char="." rowspan="1" colspan="1">16.9</td><td align="center" rowspan="1" colspan="1">14.9 to 19.2</td><td align="char" char="." rowspan="1" colspan="1">&lt;.00001</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">MSH2</italic> (LP/P)</td><td align="center" rowspan="1" colspan="1">2,610</td><td align="char" char="(" rowspan="1" colspan="1">800 (30.7)</td><td align="char" char="(" rowspan="1" colspan="1">1,810 (69.3)</td><td align="char" char="." rowspan="1" colspan="1">11.5</td><td align="center" rowspan="1" colspan="1">10.5 to 12.5</td><td align="char" char="." rowspan="1" colspan="1">&lt;.00001</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">MSH6</italic> (LP/P)</td><td align="center" rowspan="1" colspan="1">3,650</td><td align="char" char="(" rowspan="1" colspan="1">547 (15.0)</td><td align="char" char="(" rowspan="1" colspan="1">3,103 (85.0)</td><td align="char" char="." rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">4.2 to 5.0</td><td align="char" char="." rowspan="1" colspan="1">&lt;.00001</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">PMS2</italic> (LP/P)</td><td align="center" rowspan="1" colspan="1">4,100</td><td align="char" char="(" rowspan="1" colspan="1">506 (12.3)</td><td align="char" char="(" rowspan="1" colspan="1">3,594 (87.7)</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">3.3 to 4.0</td><td align="char" char="." rowspan="1" colspan="1">&lt;.00001</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> (pLOF)</td><td align="center" rowspan="1" colspan="1">33</td><td align="char" char="(" rowspan="1" colspan="1">21 (63.6)</td><td align="center" rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">45.3</td><td align="center" rowspan="1" colspan="1">21.3 to 101.0</td><td align="char" char="." rowspan="1" colspan="1">&lt;.00001</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> all missense</td><td align="center" rowspan="1" colspan="1">513<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char="(" rowspan="1" colspan="1">18 (3.5)</td><td align="char" char="(" rowspan="1" colspan="1">495 (96.5)</td><td align="char" char="." rowspan="1" colspan="1">0.94</td><td align="center" rowspan="1" colspan="1">0.6 to 1.5</td><td align="char" char="." rowspan="1" colspan="1">.91</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> BayesDel score 0.41-0.49 only</td><td align="center" rowspan="1" colspan="1">90</td><td align="char" char="(" rowspan="1" colspan="1">6 (6.7)</td><td align="char" char="(" rowspan="1" colspan="1">84 (93.3)</td><td align="char" char="." rowspan="1" colspan="1">1.85</td><td align="center" rowspan="1" colspan="1">0.8 to 4.2</td><td align="char" char="." rowspan="1" colspan="1">.14</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> BayesDel score 0.27-0.40 only</td><td align="center" rowspan="1" colspan="1">51</td><td align="char" char="(" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" rowspan="1" colspan="1">51 (100)</td><td align="char" char="." rowspan="1" colspan="1">0.25</td><td align="center" rowspan="1" colspan="1">0.02 to 4.1</td><td align="char" char="." rowspan="1" colspan="1">.33</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> BayesDel score 0.13-0.26 only</td><td align="center" rowspan="1" colspan="1">92</td><td align="char" char="(" rowspan="1" colspan="1">2 (2.2)</td><td align="char" char="(" rowspan="1" colspan="1">90 (97.8)</td><td align="char" char="." rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">0.1 to 2.3</td><td align="char" char="." rowspan="1" colspan="1">.44</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> BayesDel score &#8211;0.17-0.12 only</td><td align="center" rowspan="1" colspan="1">164</td><td align="char" char="(" rowspan="1" colspan="1">7 (4.3)</td><td align="char" char="(" rowspan="1" colspan="1">157 (95.7)</td><td align="char" char="." rowspan="1" colspan="1">1.16</td><td align="center" rowspan="1" colspan="1">0.5 to 2.5</td><td align="char" char="." rowspan="1" colspan="1">.71</td></tr><tr><td rowspan="1" colspan="1"><italic toggle="yes">RPS20</italic> BayesDel scores &#8804;&#8211;0.18</td><td align="center" rowspan="1" colspan="1">114</td><td align="char" char="(" rowspan="1" colspan="1">3 (2.6)</td><td align="char" char="(" rowspan="1" colspan="1">111 (97.4)</td><td align="char" char="." rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">0.2 to 2.2</td><td align="char" char="." rowspan="1" colspan="1">.54</td></tr><tr><td rowspan="1" colspan="1">WT (MGPT negatives)</td><td align="center" rowspan="1" colspan="1">384,445</td><td align="char" char="(" rowspan="1" colspan="1">14,269 (3.7)</td><td align="char" char="(" rowspan="1" colspan="1">370,176 (96.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>NOTE. The prevalence of CRC in each cohort: <italic toggle="yes">MLH1</italic>-positive, <italic toggle="yes">MSH2</italic>-positive, <italic toggle="yes">MSH6</italic>-positive, <italic toggle="yes">PMS2</italic>-positive, and <italic toggle="yes">RPS20</italic> pLOF heterozygotes was compared with a WT group of individuals with no VUS/LP/P using Fisher's exact test.</p></fn><fn fn-type="abbr"><p>Abbreviations: CRC, colorectal cancer; ICD, International Classification of Diseases codes; LP/P, likely pathogenic or pathogenic variant; MGPT, multigene panel testing; OR, odds ratio; pLoF, putative loss-of-function; VUS, variant of uncertain significance; WT, wild-type.</p></fn><fn fn-type="other" id="tblfn1"><label>
<sup>a</sup>
</label><p>Two in-frame insertion-deletions resulting in a missense change do not have a BayesDel score.</p></fn></table-wrap-foot></table-wrap><table-wrap position="anchor" id="tblA3" orientation="portrait"><label>TABLE A3.</label><caption><p>GDV Scheme</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th colspan="10" rowspan="1">Genetic Evidence</th></tr><tr><th rowspan="1" colspan="1">Evidence Type</th><th align="center" colspan="6" rowspan="1">Information Type</th><th align="center" rowspan="1" colspan="1">Points</th><th align="center" rowspan="1" colspan="1">Points Given</th><th align="center" rowspan="1" colspan="1">Max Score</th></tr></thead><tbody valign="top"><tr><td rowspan="6" colspan="1">Case-control data (must have lower 95% CI &gt; 1.5 for positive points and a OR &lt; 1.2 OR and lower bound CI of &lt;0.5 for negative points)</td><td colspan="6" rowspan="1">Phenotype of positives in study matches the propose gene disease relationship</td><td rowspan="1" colspan="1">1 (per study)</td><td rowspan="1" colspan="1"/><td align="char" char="." rowspan="12" colspan="1">22</td></tr><tr><td colspan="6" rowspan="1">Lower value 95% CI is &gt; 2</td><td rowspan="1" colspan="1">1 (per study)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="6" rowspan="1">Methodology of variant detection should be with equivalent analytical performance between cases and controls</td><td rowspan="1" colspan="1">1 (per study)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="6" rowspan="1">Matched cases and controls for demographics</td><td rowspan="1" colspan="1">1 (per study)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="6" rowspan="1">Matched cased and controls for ancestry</td><td rowspan="1" colspan="1">1 (per study)</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="6" rowspan="1">Equivalently evaluated cases and controls for the phenotype and family history</td><td rowspan="1" colspan="1">1 (per study)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="4" colspan="1">Case-level data<break/>Noncommon variant, no other evidence 0.1 pt; AR: half pts per variant; for GDR with assumed or demonstrated low penetrance, pLoF 2pts are not applicable. Use the non-pLoF row to assign appropriate weight</td><td rowspan="1" colspan="1">Variant type</td><td rowspan="1" colspan="1">De novo?</td><td rowspan="1" colspan="1">Functional data or constrained region?</td><td rowspan="1" colspan="1">Segregating &gt;2 and &lt;7 meioses in family OR LOD &#8805;0.9 and &lt;2.1</td><td rowspan="1" colspan="1">Segregating &gt;6 meioses in family OR LOD &#8805;2.1</td><td rowspan="1" colspan="1">Hotspot?</td><td rowspan="1" colspan="1">Points per patient with variant</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">(+1 pt)</td><td rowspan="1" colspan="1">(+0.5 pt)</td><td rowspan="1" colspan="1">(+0.5 pt)</td><td rowspan="1" colspan="1">(+1 pt)</td><td rowspan="1" colspan="1">(+0.5 pt)</td><td align="center" rowspan="1" colspan="1">0.1 (default) to 2 (max)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">pLoF (consistent with genetic data)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No. of convincing publications</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0-3 (not to exceed total patient points)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="2" colspan="1">Statistics</td><td colspan="6" rowspan="1">Internally calculated genome-wide significant (<italic toggle="yes">P</italic> &lt; 1 &#215; 10<sup>-6</sup>) excess of de novos in large cohort exome study can count as 1 patient</td><td align="center" rowspan="1" colspan="1">0-1</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="6" rowspan="1">AR disease with extensive pedigree, LOD score &gt;3 (at least 4 affected in 8 meiosis)</td><td align="center" rowspan="1" colspan="1">0-1</td><td rowspan="1" colspan="1"/></tr><tr><th colspan="10" rowspan="1">
<bold>Experimental Evidence</bold>
</th></tr><tr><td rowspan="1" colspan="1">
<bold>Evidence Category</bold>
</td><td colspan="5" align="center" rowspan="1">
<bold>Evidence Type</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Points</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>Points given</bold>
</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>Max score</bold>
</td></tr><tr><td rowspan="1" colspan="1">Function</td><td colspan="5" rowspan="1">Biochemical function</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="3" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Protein interaction</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Expression</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Gene disruption</td><td colspan="5" rowspan="1">In vitro experiments show the same disease pathology after similar genetic modification</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="2" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Determination of mechanism consistent with patient-reported alterations: WT transfection rescues mutation-expressing cells OR dosage experiments show dominant negative or gain-of-function mechanism</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Model organism</td><td colspan="5" rowspan="1">Gene function similar to the pathology of human disease</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="6" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Phenotype and genotype match human disease</td><td align="center" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">SOMATIC (cancer):</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Same truncating/frameshift alteration is identified in appropriate tumors</td><td align="center" rowspan="3" colspan="1">1 or 2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Missense alterations in the gene identified in appropriate tumor AND reported in at least 3 patient tumors AND functionally validated</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td colspan="5" rowspan="1">Gene is frequently mutated in appropriate tumor (larger data sets)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">
<bold>GDV</bold>
<xref rid="tblfn2" ref-type="table-fn">
<sup>
<bold>a</bold>
</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">Points<xref rid="tblfn3" ref-type="table-fn"><sup>b</sup></xref></td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">Disputed</td><td align="center" rowspan="1" colspan="1">&lt;0</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">No evidence</td><td align="center" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">Limited</td><td align="center" rowspan="1" colspan="1">&gt;0-7</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">8-12</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">Strong</td><td align="center" rowspan="1" colspan="1">13+</td><td rowspan="1" colspan="1"/></tr><tr><td colspan="8" rowspan="1">Definitive</td><td align="center" rowspan="1" colspan="1">17+ and MOD known</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>Abbreviations: GDR, gene-disease relationship; GDV, gene-disease validity; LOD,logarithm of the odds; MOD, mechanism of disease; OR, odds ratio; pLoF, putative loss-of-function; WT, wild-type.</p></fn><fn fn-type="other" id="tblfn2"><label>
<sup>a</sup>
</label><p>Use caution characterizing GDR as moderate or higher for common cancer types without at least one supportive case-control study/analysis.</p></fn><fn fn-type="other" id="tblfn3"><label>
<sup>b</sup>
</label><p>Must have Genetic Evidence points to assign any points (if experimental evidence only = No evidence).</p></fn></table-wrap-foot></table-wrap><table-wrap position="anchor" id="tblA4" orientation="portrait"><label>TABLE A4.</label><caption><p>Literature Review of Reported Families With <italic toggle="yes">RPS20</italic> Variants</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="1" colspan="1">Publication</th><th align="center" rowspan="1" colspan="1">Family</th><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">Genotype</th><th align="center" rowspan="1" colspan="1">Consequence</th><th align="center" rowspan="1" colspan="1">Sex</th><th align="center" rowspan="1" colspan="1">Phenotype (age at diagnosis, years)</th></tr></thead><tbody valign="top"><tr><td rowspan="8" colspan="1">Nieminen et al<sup><xref rid="b2" ref-type="bibr">2</xref></sup><break/>PMID: 24941021</td><td align="char" char="." rowspan="8" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1</td><td rowspan="8" colspan="1">c.147dupA</td><td rowspan="8" colspan="1">Putative loss-of-function</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Sigmoid colon (75)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Ascending colon (24), transverse colon (60)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Transverse colon (52)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Ascending colon (64)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Cecum (50), rectum (59)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Sigmoid colon (43), rectum (45)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Descending colon (54)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Rectum (33)</td></tr><tr><td rowspan="2" colspan="1">Broderick et al<sup><xref rid="b5" ref-type="bibr">5</xref></sup><break/>PMID: 27713038</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">c.181_182delTT p.Leu61GlufsTer11</td><td rowspan="1" colspan="1">Putative loss-of-function</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Colon (39)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">c.160G&gt;C p.Val54Leu</td><td rowspan="1" colspan="1">Missense</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Colon (41)</td></tr><tr><td rowspan="8" colspan="1">Thompson et al<sup><xref rid="b4" ref-type="bibr">4</xref></sup><break/>PMID: 32424863</td><td align="char" char="." rowspan="8" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">11</td><td rowspan="8" colspan="1">c.177+1G&gt;A</td><td rowspan="8" colspan="1">Putative loss-of-function</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Colon (61), polyps</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Colon (38), polyps</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Colon (56), polyps</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Polyps (63)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Polyps (45)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Unaffected (42)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Unaffected (19)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Unaffected (22)</td></tr><tr><td rowspan="6" colspan="1">Djursby et al<sup><xref rid="b3" ref-type="bibr">3</xref></sup><break/>PMID: 33193653</td><td align="char" char="." rowspan="6" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">19</td><td rowspan="6" colspan="1">c.98A&gt;T p.Glu33Val</td><td rowspan="6" colspan="1">Missense</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Colon (67, 73)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Cecum (37), rectum (73)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Colon (60)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Vulva (47)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">CRC (59)</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Colon (24)</td></tr><tr><td rowspan="1" colspan="1">Amiot et al<sup><xref rid="b6" ref-type="bibr">6</xref></sup><break/>PMID: 39920491</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">c.115_116del p.Leu39Aspfs*33</td><td rowspan="1" colspan="1">Putative loss-of-function</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Rectum (35), breast (42), polyps</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>Abbreviation: CRC, colorectal cancer.</p></fn></table-wrap-foot></table-wrap></app></app-group><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez Ace&#241;ero</surname><given-names>MJ</given-names></name><name name-style="western"><surname>D&#237;az Del Arco</surname><given-names>C</given-names></name></person-group><article-title>Hereditary gastrointestinal tumor syndromes: When risk comes with your genes</article-title><source>Curr Issues Mol Biol</source><volume>46</volume><fpage>6440</fpage><lpage>6471</lpage><year>2024</year><pub-id pub-id-type="pmid">39057027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb46070385</pub-id><pub-id pub-id-type="pmcid">PMC11275188</pub-id></mixed-citation></ref><ref id="b2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieminen</surname><given-names>TT</given-names></name><name name-style="western"><surname>O'Donohue</surname><given-names>MF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency</article-title><source>Gastroenterology</source><volume>147</volume><fpage>595</fpage><lpage>598.e5</lpage><year>2014</year><pub-id pub-id-type="pmid">24941021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.06.009</pub-id><pub-id pub-id-type="pmcid">PMC4155505</pub-id></mixed-citation></ref><ref id="b3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djursby</surname><given-names>M</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>MB</given-names></name><name name-style="western"><surname>Frederiksen</surname><given-names>JH</given-names></name><etal>et al</etal></person-group><article-title>New pathogenic germline variants in very early onset and familial colorectal cancer patients</article-title><source>Front Genet</source><volume>11</volume><fpage>566266</fpage><year>2020</year><pub-id pub-id-type="pmid">33193653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2020.566266</pub-id><pub-id pub-id-type="pmcid">PMC7541943</pub-id></mixed-citation></ref><ref id="b4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>BA</given-names></name><name name-style="western"><surname>Snow</surname><given-names>AK</given-names></name><name name-style="western"><surname>Koptiuch</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>A novel ribosomal protein S20 variant in a family with unexplained colorectal cancer and polyposis</article-title><source>Clin Genet</source><volume>97</volume><fpage>943</fpage><lpage>944</lpage><year>2020</year><pub-id pub-id-type="pmid">32424863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cge.13757</pub-id></mixed-citation></ref><ref id="b5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broderick</surname><given-names>P</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>SE</given-names></name><name name-style="western"><surname>Chubb</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients&#8212;A systematic review</article-title><source>Gastroenterology</source><volume>152</volume><fpage>75</fpage><lpage>77.e4</lpage><year>2017</year><pub-id pub-id-type="pmid">27713038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2016.09.041</pub-id><pub-id pub-id-type="pmcid">PMC5860724</pub-id></mixed-citation></ref><ref id="b6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amiot</surname><given-names>J</given-names></name><name name-style="western"><surname>Gubeljak</surname><given-names>L</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>New RPS20 gene variant in colorectal cancer diagnosis: Insight from a large series of patients</article-title><source>Fam Cancer</source><volume>24</volume><fpage>22</fpage><year>2025</year><pub-id pub-id-type="pmid">39920491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-025-00446-y</pub-id></mixed-citation></ref><ref id="b7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>S</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>N</given-names></name><name name-style="western"><surname>Bale</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title><source>Genet Med</source><volume>17</volume><fpage>405</fpage><lpage>424</lpage><year>2015</year><pub-id pub-id-type="pmid">25741868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmcid">PMC4544753</pub-id></mixed-citation></ref><ref id="b8"><label>8.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>The Clinical Genome Resource</collab></person-group><article-title>RPS20 gene-disease validity</article-title><ext-link xlink:href="https://search.clinicalgenome.org/kb/genes/HGNC:10405" ext-link-type="uri">https://search.clinicalgenome.org/kb/genes/HGNC:10405</ext-link></mixed-citation></ref><ref id="b9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horton</surname><given-names>C</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing</article-title><source>JAMA Oncol</source><volume>10</volume><fpage>212</fpage><lpage>219</lpage><year>2024</year><pub-id pub-id-type="pmid">37924330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2023.5586</pub-id><pub-id pub-id-type="pmcid">PMC10625669</pub-id></mixed-citation></ref><ref id="b10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karczewski</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Francioli</surname><given-names>LC</given-names></name><name name-style="western"><surname>Tiao</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><fpage>434</fpage><lpage>443</lpage><year>2020</year><pub-id pub-id-type="pmid">32461654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmcid">PMC7334197</pub-id></mixed-citation></ref><ref id="b11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiffin</surname><given-names>N</given-names></name><name name-style="western"><surname>Minikel</surname><given-names>E</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Using high-resolution variant frequencies to empower clinical genome interpretation</article-title><source>Genet Med</source><volume>19</volume><fpage>1151</fpage><lpage>1158</lpage><year>2017</year><pub-id pub-id-type="pmid">28518168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2017.26</pub-id><pub-id pub-id-type="pmcid">PMC5563454</pub-id></mixed-citation></ref><ref id="b12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>BJ</given-names></name></person-group><article-title>PERCH: A unified framework for disease gene prioritization</article-title><source>Hum Mutat</source><volume>38</volume><fpage>243</fpage><lpage>251</lpage><year>2017</year><pub-id pub-id-type="pmid">27995669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.23158</pub-id><pub-id pub-id-type="pmcid">PMC5299048</pub-id></mixed-citation></ref><ref id="b13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>SRplot: A free online platform for data visualization and graphing</article-title><source>PLoS One</source><volume>18</volume><fpage>e0294236</fpage><year>2023</year><pub-id pub-id-type="pmid">37943830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0294236</pub-id><pub-id pub-id-type="pmcid">PMC10635526</pub-id></mixed-citation></ref><ref id="b14"><label>14.</label><mixed-citation publication-type="webpage"><comment>Reference deleted</comment></mixed-citation></ref><ref id="b15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>ED</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>K</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Classification of genes: Standardized clinical validity assessment of gene-disease associations aids diagnostic exome analysis and reclassifications</article-title><source>Hum Mutat</source><volume>38</volume><fpage>600</fpage><lpage>608</lpage><year>2017</year><pub-id pub-id-type="pmid">28106320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.23183</pub-id><pub-id pub-id-type="pmcid">PMC5655771</pub-id></mixed-citation></ref><ref id="b16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schubert</surname><given-names>SA</given-names></name><name name-style="western"><surname>Morreau</surname><given-names>H</given-names></name><name name-style="western"><surname>de Miranda</surname><given-names>NFCC</given-names></name><etal>et al</etal></person-group><article-title>The missing heritability of familial colorectal cancer</article-title><source>Mutagenesis</source><volume>35</volume><fpage>221</fpage><lpage>231</lpage><year>2020</year><pub-id pub-id-type="pmid">31605533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mutage/gez027</pub-id><pub-id pub-id-type="pmcid">PMC7352099</pub-id></mixed-citation></ref><ref id="b17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Te Paske</surname><given-names>IBAW</given-names></name><name name-style="western"><surname>Ligtenberg</surname><given-names>MJL</given-names></name><name name-style="western"><surname>Hoogerbrugge</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Candidate gene discovery in hereditary colorectal cancer and polyposis syndromes-considerations for future studies</article-title><source>Int J Mol Sci</source><volume>21</volume><fpage>8757</fpage><year>2020</year><pub-id pub-id-type="pmid">33228212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21228757</pub-id><pub-id pub-id-type="pmcid">PMC7699508</pub-id></mixed-citation></ref><ref id="b18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Francioli</surname><given-names>LC</given-names></name><name name-style="western"><surname>Goodrich</surname><given-names>JK</given-names></name><etal>et al</etal></person-group><article-title>A genomic mutational constraint map using variation in 76,156 human genomes</article-title><source>Nature</source><volume>625</volume><fpage>92</fpage><lpage>100</lpage><year>2024</year><pub-id pub-id-type="pmid">38057664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06045-0</pub-id><pub-id pub-id-type="pmcid">PMC11629659</pub-id></mixed-citation></ref><ref id="b19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korphaisarn</surname><given-names>K</given-names></name><name name-style="western"><surname>Morris</surname><given-names>V</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JS</given-names></name><etal>et al</etal></person-group><article-title>Signet ring cell colorectal cancer: Genomic insights into a rare subpopulation of colorectal adenocarcinoma</article-title><source>Br J Cancer</source><volume>121</volume><fpage>505</fpage><lpage>510</lpage><year>2019</year><pub-id pub-id-type="pmid">31406299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-019-0548-9</pub-id><pub-id pub-id-type="pmcid">PMC6738104</pub-id></mixed-citation></ref><ref id="b20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodan</surname><given-names>R</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>Genetic/familial high-risk assessment: Colorectal, endometrial, and gastric, version 3.2024, NCCN Clinical Practice Guidelines in oncology</article-title><source>J Natl Compr Canc Netw</source><volume>22</volume><fpage>695</fpage><lpage>711</lpage><year>2024</year><pub-id pub-id-type="pmid">39689429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2024.0061</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>